<DOC>
	<DOCNO>NCT02741596</DOCNO>
	<brief_summary>This study open-label , long term safety efficacy study evaluate DX-2930 prevent acute angioedema attack patient Type I Type II HAE .</brief_summary>
	<brief_title>Long-term Safety Efficacy Study DX-2930 Prevent Acute Angioedema Attacks Patients With Type I Type II HAE</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<criteria>Male female HAE subject 12 year age old time screen Documented diagnosis HAE , Type I II A historical baseline HAE attack rate least 1 attack per 12 week Adult subject caregiver subject age 18 willing able read , understand , sign inform consent form . Subjects age 12 17 , whose caregiver provide informed consent , willing able read , understand sign assent form . Males female fertile sexually active must adhere contraception requirement duration study Discontinued DX293003 enrollment reason . If rolling DX293003 , presence important safety concern would preclude participation study . Concomitant diagnosis another form chronic , recurrent angioedema , acquire angioedema ( AAE ) , HAE normal C1INH ( also know HAE Type III ) , idiopathic angioedema , recurrent angioedema associate urticaria . Dosing investigational drug ( include DX2930 HAE therapy ) exposure investigational device within 4 week prior screen . Exposure angiotensinconverting enzyme ( ACE ) inhibitor within 4 week prior screen newly initiate dose modification estrogencontaining medication systemic absorption ( oral contraceptive hormonal replacement therapy ) 3 month prior screen visit . Unwilling discontinue use longterm prophylactic therapy HAE ( C1INH , attenuate androgen , antifibrinolytics ) within 3 week start DX2930 treatment . Any following liver function test abnormality : alanine aminotransferase ( ALT ) &gt; 3x upper limit normal , aspartate aminotransferase ( AST ) &gt; 3x upper limit normal , total bilirubin &gt; 2x upper limit normal ( unless bilirubin elevation result Gilbert 's Syndrome ) . Pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>DX-2930</keyword>
	<keyword>Dyax</keyword>
	<keyword>Hereditary Angioedema</keyword>
</DOC>